An independent peptide reference — no sellers, every claim sourced

Adamax

Also known as Adamax peptide

A peptide sold to the nootropic market whose identity cannot be established from any non-vendor source.

preclinical Neuro & cognition research chemical

At a glance

Category
Neuro & cognition
Status
research chemical
Route
Sold as a lyophilised powder; the nootropic market uses it subcutaneously or nasally. No route has been validated for any purpose.
Half-life
No published pharmacokinetics of any kind. Any figure that circulates is unsourced.
Sequence
Not established. Vendors describe an N-acetylated, adamantane-conjugated Semax analogue, but this comes only from vendor material, is not confirmed by any independent characterisation, and vendor descriptions disagree 12.

Adamax is sold online as a nootropic 'research chemical' peptide. PeptideX could not establish what it actually is from any independent source. A PubMed search returns no record describing a peptide of this name - the hits belong to an unrelated machine-learning optimisation algorithm called Adamax 1 - and ClinicalTrials.gov holds no study 2. The only descriptions of its structure come from vendor and content-farm pages, which are not a usable source of fact and which do not even agree with one another: several present it as a Semax derivative (an N-acetylated, adamantane-conjugated analogue of the ACTH(4-10) fragment Met-Glu-His-Phe-Pro-Gly-Pro, the same core as Semax), while at least one conflates Adamax with the unrelated peptide P21. Because the identity itself is unverified, the entry is kept deliberately minimal rather than repeating a structure and mechanism that no independent source supports.

Doping status: Cannot be classified with confidence, because the substance is not reliably identified. If it is a non-approved synthetic peptide as vendors claim, a non-approved substance would fall under the S0 residual category and be prohibited at all times - an inference, not a listing

Checked against the WADA 2026 Prohibited List. For a specific product and country, Global DRO is the lookup athletes are expected to use — the List names substances, not brand names.

This is a short entry. There is little or no published research on this compound, so there is correspondingly little to report. Empty dosing or reconstitution sections mean no credible figures exist — not that they were left out.

Mechanism of action

No mechanism is described here, on purpose. Giving one would require accepting a structure for Adamax, and no structure can be confirmed from any independent source: there is no peer-reviewed paper on a peptide of this name 1, and the only structural descriptions are from vendors, which conflict with each other.

What can be said is limited to naming the claim and its problem. Sellers most often present Adamax as a modified Semax - Semax being the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, itself derived from the ACTH(4-10) melanocortin fragment and covered separately on this site - with an added acetyl group and an adamantane moiety said to improve stability and brain penetration. Even if that description were accurate, no published study has tested such a molecule for any effect, so its pharmacology would still be unknown. Since the description cannot be verified in the first place, treating it as a fact would be exactly the kind of vendor-sourced invention this reference exists to avoid.

What the research shows

There is no evidence, and there is no confirmed compound to have evidence about. No peer-reviewed study describes a peptide called Adamax 1 and no clinical trial is registered 2. Every claim made for it - structure, mechanism, benefit and dose - traces to vendor and content-farm pages.

Research in humans

No human study of any kind. No trial, no case series, no pharmacokinetic or safety data 12.

Animal and lab research

No verifiable animal study of a peptide called Adamax was found 1. Any preclinical claim made on retail pages appears to be borrowed from the literature on Semax rather than generated with this product.

Caveats. The fundamental limitation is identity: the substance sold as Adamax is not defined by any independent source, so nothing downstream of that - purity, dose, effect, safety - can be assessed. A grey-market powder of unverified composition is exactly what the buyer receives.

What it is used for

  • Sold and self-administered as a nootropic, on the basis of claims transferred from Semax rather than any study of this product 1
  • No validated use of any kind exists

Dosing

  • There is no dose. No dose-finding study, no pharmacokinetics, no maximum tolerated dose and no clinical protocol exist 12.
  • A self-administration practice circulates in the nootropic market - the powder is reconstituted and used subcutaneously or nasally - but no protocol is tabulated here, because tabulating a schedule for a compound whose identity is unverified would lend it a credibility it has not earned. The milligram figures that circulate track the vial size and are copied between vendor pages.
  • Any dosing figure presented for Adamax is inventing a number for a substance nobody has characterised.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Safety

Side effects

  • Unknown. No safety data exist for a peptide of this name 12, and the absence of reported effects reflects the absence of any study, not safety
  • The identity and purity of what is sold cannot be verified by the buyer, and no independent analysis has been published - so even the active ingredient is uncertain

Do not use if

  • Everyone, in the practical sense: a substance of unconfirmed identity, with no characterised pharmacology and no safety data, has no setting in which its risk-benefit ratio can be assessed
  • Pregnancy, breastfeeding, children and adolescents - no data of any kind

Interactions

Not studied, and not assessable while the identity of the substance is unconfirmed 1.

Sources